You are here

Therapeutic Development of RNAi-based inhibitors against the Hepatitis Delta Viru

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI104007-01A1
Agency Tracking Number: R43AI104007
Amount: $389,582.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA12-088
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
SANTA CRUZ, CA 95060-5790
United States
DUNS: 13494781
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (831) 426-7700
Business Contact
Phone: (831) 426-7700
Research Institution

DESCRIPTION (provided by applicant): Hepatitis D virus (HDV) infection is the most severe type of viral hepatitis, often causing accelerated liver damage that leads to end-stage liver disease. About 10-15 million individuals are infected by HDV worldwide.The absence of an effective treatment for acute forms of the disease and the limited efficacy of current treatments for the chronic infection justify novel strategies towards the development of anti-HDV therapeutics. The lack of HDV-encoded druggable targets that are suitable for conventional therapeutic modalities such as small molecules and antibodies makes RNA interference an attractive alternative approach to target this virus. In this Phase I SBIR proposal, we propose to develop anti-HDV inhibitors using a platform developed by SomaGenics for its hepatitis C program in which chemically modified, synthetic small shRNAs (sshRNAs), formulated with lipid nanoparticles, produced effective viral knockdown in preclinical animal models. To effectively in

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government